Avid Bioservices Inc (CDMO)

[biopharm]

Patents based on PS Targeting (was messaged about me forgetting Salk Institute so will include / build a list of all Biotechs that have PS Targeting interest....)

..
..

We inch further along as Ampersand wonders what is going on ...and for those that have sent in requests to make public the investigations to SEC/ FBI / DOJ / FDA etc much thanks and a little bit more work to do....but anyone looking to maximize shareholder value one must send all requests in again and update with relevant information

I am not going to puy out some template because being hit by all directions and by various letters then it will not be swept under the rug. As now, Ampersand is NOT on the side of the Avid CDMO but on their own side

All one needs to know is Merck will likely try to outpace Biogen in Alzheimer's and PS Targeting required ( those names not being published yet here but they will show up at federal agencies ) so send in again all letters ...till Ampersand proves they are not backing down and taking bribes as Teijin Pharma knows PS Targeting REQUIRED for Alzheimer's

I expect something bigger to happen here within a week

Merck $MRK struck its deal with Japan’s Teijin Pharma, including an upfront and milestones which it didn’t disclose (and rarely does). Now its neuroscience R&D group will take over development, reserving a royalty split if this one ever makes it to the market.

Merck has the most advanced BACE drug – verubecestat, which moves upstream to halt development of amyloid beta – in development. Back in February Merck shuttered its EPOCH trial for verubecestat in mild-to-moderate Alzheimer’s after the external data monitoring committee concluded that the drug was a bust, with “virtually” no chance of success. But the pharma giant is continuing its work on the drug with a separate Phase III in very early stage prodromal patients.

..
...
https://endpts.com/right-on-the-heels-of-a-phiii-failure-merck-neuroscience-doubles-down-with-a-new-drug-targeting-tau/